We are live on ! Find out more
SP

Steelhead Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 0.01%
This Fund
S&P 500
This Quarter Est. Return
+0.02%
1 Year Est. Return
+0.01%
3 Year Est. Return
+0.04%
5 Year Est. Return
+0.04%
10 Year Est. Return
+4.69%
AUM
$1.35B
AUM Growth
+$185M
Cap. Flow
-$1B
Cap. Flow %
-74.37%
Top 10 Hldgs %
49.73%
Holding
43
New
1
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$687K

Top Sells

Rank Stock Value
1
CNMD icon
CONMED
CNMD
+$764K

Sector Composition

Rank Sector Weight
1 Healthcare 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$36.3B
$721K 0.05%
+3,600
New +$687K
CNMD icon
2
CONMED
CNMD
$1.29B
– –
-7,980
Closed -$764K

Similar funds

HRES
Heitman Real Estate Securities Chicago, Illinois $1.39B AUM 6.59% 1-Year Est. Return
SRAIM
Scheer Rowlett & Associates Investment Management Toronto, Ontario, Canada $1.39B AUM 49.24% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.39B AUM 18.33% 1-Year Est. Return
TCC
Trans-Canada Capital Montreal, Quebec, Canada $1.39B AUM 16.61% 1-Year Est. Return
SC
Sagefield Capital Dallas, Texas $1.39B AUM 60.14% 1-Year Est. Return
BCP
Blue Chip Partners Farmington Hills, Michigan $1.39B AUM 22.32% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Steelhead Partners's Q3 2022 Portfolio in Review

As of Q3 2022, Steelhead Partners held 43 positions worth $1.35B, up 16% from $1.17B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Steelhead Partners withdrew a net $1B in Q3 2022, closing 1 position. Its most notable exit was CONMED, an estimated $764K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 0.05% of assets, down from 0.07% a quarter earlier.

Against the trend, Steelhead Partners opened a new position in Alnylam Pharmaceuticals worth $721K.

  • Steelhead Partners's largest Q3 2022 buy was Alnylam Pharmaceuticals: 3,600 shares worth $721K.
  • Steelhead Partners fully exited CONMED in Q3 2022, selling an estimated $764K.
  • Steelhead Partners's ten largest holdings make up 50% of its $1.35B portfolio in Q3 2022.
  • Steelhead Partners opened 1 new position and closed 1 in Q3 2022.
  • Steelhead Partners's portfolio value rose 16% quarter-over-quarter to $1.35B.

Based on Steelhead Partners's 13F filing for Q3 2022, filed 14 Nov 2022.